Impact of New Systemic Therapies on Overall Survival of Patients with Metastatic Castration Resistant Prostate Cancer in a Hospital-based Registry

BACKGROUND: In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Prostate Cancer Prostatic Dis
Main Authors: Francini, Edoardo, Gray, Kathryn P., Shaw, Grace K., Evan, Carolyn P., Hamid, Anis A., Perry, Caitlin E., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher J.
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2019
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869825/
https://ncbi.nlm.nih.gov/pubmed/30643173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-018-0121-2
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla